ANI PHARMACEUTICALS INC
ANIP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ANIP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ANIP
ANI Pharmaceuticals is a diversified pharmaceutical company operating in Rare Disease, Brands, and Generics segments, anchored by its flagship Cortrophin Gel and the ophthalmology products ILUVIEN and YUTIQ.
Key risk: Patent expiries for YUTIQ and ILUVIEN
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.67B
Cash Runway
—
Lead Asset
carboprost (Approved)Next Catalyst
Phase3_Topline · Dec 1, 2026Financial data as of Jun 30, 2026.
Tracking 15 pipeline candidates · 3 clinical trials · 4 catalysts · 35 FDA decisions for ANI PHARMACEUTICALS INC.
ANI Pharmaceuticals is a diversified pharmaceutical company operating in Rare Disease, Brands, and Generics segments, anchored by its flagship Cortrophin Gel and the ophthalmology products ILUVIEN and YUTIQ.
- As of June 30, 2026, ANI reported cash & equivalents of $360.2M, total revenue of $266.0M, net income of $24.7M, shareholders' equity of $403.7M, and total debt of $301.5M [sec].
- The company operates three segments: Rare Disease (Cortrophin Gel, ILUVIEN, YUTIQ), Brands (~20 branded products in genericized markets), and Generics (including contract manufacturing) [sec · filed 2026-04-09].
- In 2025, ANI achieved revenues of $883.4M and adjusted non-GAAP EBITDA of $229.8M, exceeding its corporate targets [sec · filed 2026-04-09].
- The Generics segment delivered 12 product launches in 2025 and has maintained a number-two U.S. market position by volume [sec · filed 2026-04-09][sec · filed 2025-04-10].
- ANI owns and operates three U.S.-based pharmaceutical manufacturing facilities [sec · filed 2026-04-09].
What works
- Strong commercial execution in Rare Disease, with Cortrophin Gel driving ACTH market and share growth, and ILUVIEN/YUTIQ adding full-quarter sales after the Alimera acquisition [sec_mda · as of 2025-11-07].
- Generics segment has shown consistent double-digit growth for three consecutive years (2022-2024) and delivered 17 new product launches in 2024 [sec · filed 2025-04-10].
- The company's financial resources, including working capital and available borrowings under the 2024 Credit Facility, are expected to meet working capital and debt obligations for at least 12 months from filing [sec_mda · as of 2026-08-07].
- Operational discipline and a strong R&D engine support a consistent cadence of new product introductions across segments [sec · filed 2026-04-09].
What to weigh
- The Brands segment consists of products in highly genericized markets, which may face pricing and volume pressure [sec · filed 2026-04-09].
- The company carries $301.5M in total debt as of June 30, 2026, which could constrain financial flexibility [sec].
- Patent/exclusivity expiries for key products YUTIQ (2028-01-12) and ILUVIEN (2028-11-07) pose a risk to future Rare Disease revenue [upcoming catalysts].
- The company may need to raise additional equity or incur more debt to fund future acquisitions, which could dilute shareholders or increase leverage [sec_mda · as of 2026-08-07].
From the filings
Quoted directly from source documents.
ANI's financial resources are sufficient for at least the next 12 months from the filing date.
“will be sufficient to enable us to meet our working capital requirements and debt obligations for at least the next 12 months from the date of filing of this report”
SEC MD&A · August 7, 2026
Catalyst timeline
- 2026-12-01 · Phase3_Topline — Phase 3 Topline: The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Af — Topline data from a Phase 3 trial evaluating two YUTIQ implants versus sham for chronic non-infectious intraocular inflammation.
- 2028-01-12 · Patent_Expiry · YUTIQ — Patent/Exclusivity Expiry: YUTIQ — Patent/exclusivity expiry for YUTIQ, which could open the door to generic competition.
- 2028-11-07 · Patent_Expiry · ILUVIEN — Patent/Exclusivity Expiry: ILUVIEN — Patent/exclusivity expiry for ILUVIEN, potentially affecting market exclusivity.
- 2043-10-27 · Patent_Expiry · PURIFIED CORTROPHIN GEL — Patent/Exclusivity Expiry: PURIFIED CORTROPHIN GEL — Long-dated patent/exclusivity expiry for Cortrophin Gel, providing extended protection.
Risks & what to watch (4)›
Key risks
- Patent expiries for YUTIQ and ILUVIEN — YUTIQ patent expires 2028-01-12 and ILUVIEN expires 2028-11-07, potentially reducing Rare Disease revenue [upcoming catalysts].
- High debt level — Total debt of $301.5M as of June 30, 2026 may limit financial flexibility and increase interest costs [sec].
- Generic competition in Brands segment — Brands portfolio consists of products in highly genericized markets, facing pricing and volume erosion [sec · filed 2026-04-09].
- Dependence on acquisitions for growth — Future growth may require additional equity or debt financing, which could dilute or increase leverage [sec_mda · as of 2026-08-07].
What to watch
- Phase 3 topline results for YUTIQ in chronic non-infectious intraocular inflammation, expected December 1, 2026 [upcoming catalysts].
- Patent expiries for YUTIQ (January 2028) and ILUVIEN (November 2028) and their impact on Rare Disease revenue [upcoming catalysts].
- Generics segment's ability to sustain double-digit growth and new product launch cadence [sec · filed 2025-04-10].
- Integration and commercial performance of the Alimera acquisition (ILUVIEN and YUTIQ) [sec_mda · as of 2025-11-07].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run ANI PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ANI PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 1.50 · 4% dilution
Lead: Approved
15 candidates
4 upcoming, next in ~93d
0 buys · 27 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
277
Total value held
$1.83B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,747,492 | $211.3M |
| vanguard capital management llc | 1,646,128 | $126.6M |
| state street corp | 771,587 | $59.3M |
| tang capital management llc | 707,500 | $54.4M |
| goldentree asset management lp | 667,981 | $51.3M |
| deep track capital, lp | 600,000 | $46.1M |
| millennium management llc | 592,013 | $45.5M |
| arrowstreet capital, limited partnership | 564,360 | $43.4M |
| caption management, llc | 535,890 | $41.2M |
| dimensional fund advisors lp | 531,190 | $40.8M |
Showing top 10 of 277 institutional holders of ANI PHARMACEUTICALS INC. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 19.0%
- Days to cover
- 10.8
- Shares short
- 3,562,734
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANIP short interestGovernance
Frequently asked questions
What is the AI investment thesis for ANI PHARMACEUTICALS INC?
ANI Pharmaceuticals is a diversified pharmaceutical company operating in Rare Disease, Brands, and Generics segments, anchored by its flagship Cortrophin Gel and the ophthalmology products ILUVIEN and YUTIQ.
What is ANI PHARMACEUTICALS INC's lead drug candidate?
ANI PHARMACEUTICALS INC's most advanced tracked candidate is carboprost (Approved).
What is ANI PHARMACEUTICALS INC's next catalyst?
ANI PHARMACEUTICALS INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Af" — expected December 1, 2026.
Who is the CEO of ANI PHARMACEUTICALS INC?
Mr. Nikhil Lalwani is the chief executive officer of ANI PHARMACEUTICALS INC (ANIP).
Where is ANI PHARMACEUTICALS INC headquartered?
ANI PHARMACEUTICALS INC (ANIP) is headquartered in Baudette, MN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.